Predictive genetic testing in minors for late-onset conditions: a chronological and analytical review of the ethical arguments

Cara Mand,1,2 Lynn Gillam,3,4 Martin B Delatycki,1 Rony E Duncan5,6,7

ABSTRACT

Predictive genetic testing is now routinely offered to asymptomatic adults at risk for genetic disease. However, testing of minors at risk for adult-onset conditions, where no treatment or preventive intervention exists, has evoked greater controversy and inspired a debate spanning two decades. This review aims to provide a detailed longitudinal analysis and concludes by examining the debate’s current status and prospects for the future. Fifty-three relevant theoretical papers published between 1990 and December 2010 were identified, and interpretative content analysis was employed to catalogue discrete arguments within these papers. Novel conclusions were drawn from this review. While the debate’s first voices were raised in opposition of testing and their arguments have retained currency over many years, arguments in favour of testing, which appeared sporadically at first, have gained momentum more recently. Most arguments on both sides are testable empirical claims, so far untested, rather than abstract ethical or philosophical positions. The dispute, therein, lies not so much in whether minors should be permitted to access predictive genetic testing but whether these empirical claims on the relative benefits or harms of testing should be assessed.

INTRODUCTION

Predictive genetic testing, offered alongside in-depth counselling, has established itself as an accepted component of care for adults at risk of developing a late-onset genetic condition. Similarly, there is broad support for the provision of predictive testing for conditions, which manifest in childhood or adolescence, especially where there are effective interventions available during this time (eg, familial adenomatous polyposis (FAP) coli). Conversely, there is considerable controversy associated with offering these tests to minors for conditions, which rarely manifest prior to adulthood. This paper investigates this controversy.

Dispute arises when testing outcomes cannot clearly provide a benefit for the minor. Canadian investigators Bloch and Hayden, in a 1990 editorial in response to requests to perform predictive tests in minors for Huntington’s disease (HD), argued that access to predictive genetic testing should be restricted to those ≥18 years of age.1 The debate that ensued highlighted the need for guidelines to assist the practice of clinicians worldwide. In the same year as Bloch and Hayden’s seminal publication, the International Huntington Association together with the World Federation of Neurology entered the debate with the publication of the first policy statement addressing this newly controversial area.2 Subsequent years saw the publication of several more guidelines and recommendations relating to predictive testing in minors. In 2006, a systematic review of all guidelines and policy statements concerning the predictive and presymptomatic testing of minors was undertaken.3 Despite the subtle differences in the published statements, policies and guidelines, they agree in recommending against testing in minors where there is no medical benefit in the immediate future, as Borry et al discuss in their systematic review5:

‘It is clear that the availability of medical benefit is the most important justification to perform predictive and presymptomatic genetic testing in minors, regardless of the onset of the disease. The absence of medical benefit is the most important justification to defer testing until the adolescent or adult is able to make a personal decision on this matter after a full discussion and exploration of the issues.’

Almost two decades since the publication of the first guidelines concerning predictive testing in minors, considerable disagreement still exists in the literature. Opponents of testing highlight potential harms, while proponents look to testing as an opportunity to promote benefit, with each side drawing upon fundamental ethical principles to support their diametrically opposed positions. The evolution of this ethical discourse over the past 20 years, with its various arguments for and against testing, has not so far been tracked and analysed. This review aims to fill that gap, by providing a detailed chronology and mapping of how the arguments entered the discourse and developed over the years. This mapping will offer an opportunity for the debate to advance by making clear where the key points of disagreement lie.

This review is not simply a catalogue of the arguments for and against testing in minors, but rather an analysis of the longitudinal evolution of the debate, highlighting the relative emphasis given to certain arguments. This review provides a new framework for understanding the debate, bringing to the surface untested claims and highlighting the opportunities for empirical research.
RESULTS

Of the 33 discrete arguments identified, 16 opposed and 17 supported predictive genetic testing in minors. The arguments were subsequently grouped according to 10 thematic categories, four against (1A–1D) and five in favour (2A–2E) of testing. The arguments and categories are presented in box 1 and the following discussion uses this framework.

DISCUSSION

The battlefield was set in the period 1990–1994, with eight separate publications regarding predictive genetic testing in minors. At the beginning of the ethical debate, authors promoted a conservative approach, arguing against testing for minors. Eight distinct arguments against predictive testing came to light in the very first year. Indeed, the case against testing was largely established by 1994, and these initial arguments against testing appeared repeatedly in the following years. By contrast, momentum in favour of testing evolved more slowly, with most arguments beginning to surface in the mid-to-late 1990s. Beyond this broad commentary on the ‘shape’ of the discourse thus far, there is no obvious pattern.

Certain arguments are more frequently cited in the literature than others (1A.1, 1B.1, 1C.1–1C.3, 1D.1, 1D.2, 2A.1 and 2C.1). There are a number of considerations that come to bear in examining the relative frequency of each of the arguments. The prominence of an argument, in terms of the number of times it appears, provides an element of insight into the level of importance attributed to it by commentators. Repetition in these terms, though, does not necessarily connote a strong or even sound argument. Clarke points to this trap in noting that it is insufficient to, ‘look at the length of the two, rather arbitrary, lists of arguments and then come to the unwarranted conclusion that the two opposed sets are of equal force’. An argument is not intrinsically significant simply because it has appeared in the literature. It must be tested against opposing positions. That said, there is some value in a tally, to understand what authors to date have considered important.

In the last 5 years all but one (1A.6) argument has continued to appear, highlighting that the debate is ongoing, with little resolution. The debate, such as it is, has adopted a to-and-fro pattern defined by parallel lines of argument, rarely intersecting and relying heavily on fundamentally opposed positions on core principles of bioethics with no reconciliation in sight. That no arguments have ‘dropped off’ the list testifies to a prevailing inertia. No argument has gained supremacy over others. The same core arguments are cited repeatedly, with only subtle variations, suggesting that a different approach may now be required. Clinical practice has forged on ahead of the discourse and predictive genetic testing in minors has become a reality.

Formal guidelines have evolved to admit some flexibility in considering requests for predictive testing in minors, although they do not provide a framework or criteria to guide this process.

In reviewing the arguments listed in this review, two groups of claims can be identified. A minority are value claims supported by a preordained broader ethical stance, where there is no possibility of empirical investigation. Three (of 35) arguments clearly fit into this category (‘testing minors fails to respect their future autonomy’, ‘testing minors breaches their confidentiality when their results are disclosed to their parents’ and ‘it is important to avoid professional paternalism’). Of greater interest is the second group of arguments, which are all testable empirical claims that have not yet been tested. Examples of such testable, but so far untested, claims include: ‘A positive test result may lead to depression’ (1A.5); ‘Testing can...
have a negative effect on family relationships’ (1B.1); ‘Testing can decrease uncertainty’ (2A.1) and ‘Harm could result from not testing’ (2D.1). This group of untested claims forms the ethical subtext of the debate over predictive genetic testing in minors. This subtext concerns the ethics of collecting the evidence to settle the question. If most arguments are empirical claims, eminently testable, the matter at hand is whether to test these claims or if the potential outcomes of this research are too harmful to even attempt. Some argue that the harms and benefits of testing should be assessed in empirical research, while others argue that the potential for harm is too great to ethically conduct this research.

Many of the arguments for and against testing are mirror images of one another. Some authors highlight particular
outcomes as net negatives, whereas others look to the benefits associated with these same outcomes. For example, the new knowledge represented by a test result is viewed in negative terms as burdensome or else, more positively, as empowering knowledge enabling future decision-making, thereby promoting autonomy. There are underlying, mostly unacknowledged, values working to direct the commentators to one or the other interpretation. Working from the same set of ethical principles and concerns (eg, harm, benefit and autonomy), the commentators on either side of the debate have reached opposing conclusions and this sticking point is the position we remain in.

Whereas arguments in favour of predictive genetic testing of minors highlight consequences of receiving both gene-positive and gene-negative results, the arguments against predictive testing have focused heavily on the scenario in which a minor receives a gene-positive test result, largely excluding any serious analysis of potential outcomes. Of the arguments listed above, 11 of 16 assume an unfavourable test result (1A.1, 1A.3–1A.6, 1B.2 and 1C.1–1C.5). Authors appear to believe that the negative ramifications associated with this 50% probability (a gene-positive test result) are so profound that they outweigh any potential positive impact derived from a gene-negative result. Completely missed from this binary analysis is the possibility that there may be positive ramifications from a gene-positive result, or negative impacts from a gene-negative result and, importantly, the potential adverse effects of not testing.

In keeping with the overall lack of systematic work in the area, commentators have rarely discussed which of their arguments specifically apply to infants and younger children, older children or adolescents. A developmental perspective is indispensable, considering each argument as it applies along the trajectory of child and adolescent development. For this review, the authors attempted to categorise each argument by the age group most affected, specifically ‘older’ minors, ‘younger’ minors and arguments applicable to all minors. Here, ‘younger’ minors are ‘young people who do not possess the cognitive capacities that allow them to appreciate the implications of predictive testing’.5 ‘Older’ minors are considered to have

---

Figure 1 A visual representation of how the debate has evolved over the past two decades. Each black bar represents a discrete argument, indicating the year the argument first appeared in the literature, and the year it was most recently mentioned.
CONCLUSION
Some novel conclusions can be drawn from this review of the two-decade-long discourse surrounding predictive genetic testing in minors for late-onset conditions where no effective pre-adulthood preventive medical intervention exists. The discourse remains stalled, arguing in theoretical terms over whether the testing is right or wrong, without a clear in principal resolution. One explanation may be that this state of affairs is the consequence of significant and strong moral arguments on both sides of the debate. However, we suggest that the problem arises from the lack of empirical evidence to substantiate either side of the debate. Meanwhile, clinical practice and guidance have evolved to adopt a more flexible patient-centred approach. To date, published work has provided little guidance towards defining an ethical framework for applying this non-flexibility. Instead, the opposing positions roll along parallel lines, moving no closer to a critical analysis of the quality of each argument and relying on the same ethical principles of harm, benefit and autonomy to justify their opposing positions.

It is clear that the earliest arguments were opposed to testing and have retained currency, while arguments in favour were initially seen more sporadically and have only gained momentum in recent years. Many of the arguments are mirror images of one another, drawing on core ethical principles but arriving at diametrically opposed positions. Authors arguing against testing have focused heavily on the negative implications of a gene-positive test result and have failed to fully canvass the broad potential benefits and harms of gene-negative or gene-positive results, or the potential benefits and harms of not permitting testing. Most of the arguments forming the debate are in fact testable empirical claims, which have not been tested to date. Only a minority are value claims where an ethics discourse is the only means of further exploration. The dispute, therein, lies not so much in whether minors should be permitted to participate in predictive genetic testing but whether these empirical claims on the relative benefits or harms of testing should be assessed. Some authors argue that empirical evidence is required, while others point to a list of potential harms as sufficient to settle the debate and avoid both testing and research into its implications.

There remains an impasse, with little empirical evidence to guide an analysis of the assumptions and values, which underlie many of the arguments made thus far. Many of the arguments against testing highlight potential negative outcomes of testing. There are three possible responses to this situation. The first is to consider the possible negative outcomes of testing to be so onerous that we should remove the possibility of these negative outcomes by completely ceasing the practice of predictive genetic testing in minors. The second is to develop guidelines that allow clinicians to go ahead and make their own clinical and moral decisions based on their judgement in individual cases, and the third possibility is to systematically collect empirical evidence to test the claims regarding negative consequences and reform guidelines based on this evidence. We advocate the latter, which would allow the systematic collection of evidence in controlled and clearly defined settings.

REFERENCES
Feature article

Predictive genetic testing in minors for late-onset conditions: a chronological and analytical review of the ethical arguments
Cara Mand, Lynn Gillam, Martin B Delatycki and Rony E Duncan

*J Med Ethics* 2012 38: 519-524 originally published online March 8, 2012
doi: 10.1136/medethics-2011-100055

These include:

References
This article cites 56 articles, 10 of which you can access for free at:
http://jme.bmj.com/content/38/9/519

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Editor's choice (117)
- Oncology (100)
- Clinical genetics (29)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/